Type 1 diabetes patients gaining excess weight face rising insulin needs and fatty liver disease despite tight sugar control, but popular weight loss drugs like semaglutide lack approval for this group. 
In the study published in the Diabetes Technology & Therapeutics, the investigators tracked 42 overweight or obese adults with stable sugars, weight, and insulin doses over the prior year to test real-world effects. Participants averaged age 46 years with 28 years of diabetes, HbA1c near 7.4%, and body mass index over 32. Over three-quarters qualified as obese. Teams measured weight changes, total daily insulin, HbA1c, and liver scans using controlled attenuation parameter for fat and stiffness for scarring at start and 12 months. Eight patients stopped early due to stomach upset, but most tolerated treatment well.
Big Weight Drops Cut Obesity Rates
Average weight loss hit 13.3% with high significance, as 76% shed at least 5% and nearly 62% lost 10% or more. Obesity rates plunged from 76.2% to 29.4%, transforming body composition substantially.
Insulin Needs Fall with Better Sugars
HbA1c improved by 0.4% on average, with 42% gaining half a point or better drop. Total daily insulin cut by 13.6%, though dose per body weight held steady due to slimmer frames. Sugar monitor data showed no major shifts in those tracked continuously.
Liver Fat and Scars Shrink Fast
Among 23 with repeat liver scans, fatty liver prevalence crashed from 82.6% to 30.4%. Fat measures dropped 45 decibels per meter, and serious scarring fell from one-fifth to under 5%. These gains suggest broad metabolic healing.
Safe Option Opens New Doors
Gastrointestinal side effects caused most dropouts, but no severe lows or other harms emerged. Semaglutide works safely atop insulin therapy.
Practical Tool for Type 1 Weight Care
Endocrinologists gain evidence for off-label use in stable overweight type 1 patients seeking liver health alongside sugar control. Monitor stomach tolerance and liver scans to track benefits.